SELLAS Life Sciences Group, Inc.(SLS)

Description: SELLAS Life Sciences Group, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications. The company's lead product candidate is galinpepimut-S (GPS), a wilms tumor 1 targeting peptide-based cancer immunotherapeutic agent, which has entered in Phase III clinical trials for the treatment of acute myeloid leukemia; and is in various development phases as a potential treatment for ovarian cancer. It also develops nelipepimut-S (NPS) that is in Phase 2b clinical trials for the treatment of breast cancer; GALE-301 and GALE-302, which is in Phase 1/2a trials in ovarian and endometrial cancers. The company has strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and Advaxis, Inc. on a research program to evaluate, through a proof of principle trial, a clinical candidate, which comprises the combination of proprietary Lm-based antigen delivery technology and GPS. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.

---

Keywords: Cancer Biopharmaceutical Clinical Medicine Solid Tumors Oncology Breast Cancer Cancer Treatment Immunotherapies Ovarian Cancer Acute Myeloid Leukemia Antineoplastic Drugs Treatment Of Breast Cancer Hematologic Malignancies Gynaecology Treatment Of Acute Myeloid Leukemia Oncolytics Biotech Novel Cancer Endometrial Cancer Gynaecological Cancer Pembrolizumab National Park Service Ovarian And Endometrial Cancers Treatment For Ovarian Cancer

---

Home Page: www.sellaslifesciences.com

SLS Technical Analysis

Times Square Tower
New York, NY 10036
United States
Phone: 646 200 5278

---

Officers

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)